Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

NCT04516811 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

102

Enrollment

OTHER

Sponsor class

Stopped No benefit seen in 2 published inpatient RCTs (but had limitations). Press release from inpatient Recovery trial with large number of endpoints showed no benefit. CCP collected from survivors of original strain infection had no neutralisation

Conditions

COVID-19
SARS-CoV-2 Infection
Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

BIOLOGICAL: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
BIOLOGICAL: Standard of care (SOC) plus placebo

Sponsor

South African National Blood Service